Alimera Sciences to Present at Ophthalmology Innovation Summit at the American Academy of Ophthalmology Annual Meeting

ATLANTA, Oct. 9, 2014 /PRNewswire/ -- Alimera Sciences, Inc. ALIM (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that it will present at the Ophthalmology Innovation Summit (OIS) at the American Academy of Ophthalmology (AAO) annual meeting in Chicago, IL.

Dan Myers, President and Chief Executive Officer of Alimera, will discuss the recent U.S. Food and Drug Administration (FDA) approval and advantages of ILUVIEN® for the long-term treatment of diabetic macular edema (DME) during the Device, Delivery and Diagnostic Company Showcase on Thursday, October 16, 2014.

A copy of the presentation will be available on the Investor Relations section of the corporate website, at www.alimerasciences.com.

About Alimera Sciences, Inc.
Alimera Sciences, Inc., based in Alpharetta, GA, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Alimera Sciences Limited, a subsidiary of Alimera, is based in the United Kingdom and is the headquarters of Alimera's European operations.

Investor Contact:
The Ruth Group
David Burke
646-536-7009
dburke@theruthgroup.com

SOURCE Alimera Sciences, Inc.